loading

Verve Therapeutics Inc Aktie (VERV) Neueste Nachrichten

pulisher
Apr 04, 2025

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 04, 2025
pulisher
Apr 04, 2025

Verve Therapeutics Strengthens Team with Strategic Equity Awards Worth $232K - Stock Titan

Apr 04, 2025
pulisher
Apr 03, 2025

Verve Therapeutics CEO Sekar sells $40,761 in stock By Investing.com - Investing.com South Africa

Apr 03, 2025
pulisher
Apr 03, 2025

Verve therapeutics CAO Joan Nickerson sells $11,524 in stock - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

Verve Therapeutics CEO Sekar sells $40,761 in stock - Investing.com India

Apr 03, 2025
pulisher
Apr 03, 2025

Verve Therapeutics Executives Sell Shares - TradingView

Apr 03, 2025
pulisher
Apr 03, 2025

Verve therapeutics CAO Joan Nickerson sells $11,524 in stock By Investing.com - Investing.com UK

Apr 03, 2025
pulisher
Apr 01, 2025

Is Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy? - Insider Monkey

Apr 01, 2025
pulisher
Mar 31, 2025

Class Action Filed Against Verve Therapeutics, Inc. (VERV)October 28, 2024 Deadline to Join – Contact Levi & Korsinsky - ACCESS Newswire

Mar 31, 2025
pulisher
Mar 30, 2025

Swiss National Bank Purchases 18,000 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World

Mar 30, 2025
pulisher
Mar 29, 2025

Did Verve Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate– VERV - ACCESS Newswire

Mar 29, 2025
pulisher
Mar 26, 2025

Investigation announced for Long-Term Investors in shares - openPR.com

Mar 26, 2025
pulisher
Mar 26, 2025

Pixalate Releases Q4 2024 United Kingdom Connected TV (CTV) Ad Supply Chain Trends Report: Samsung Smart TV Leads in Device Market Share (30%); Ad Fraud (IVT) Rate Hits 16% - GlobeNewswire Inc.

Mar 26, 2025
pulisher
Mar 25, 2025

Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts - Seeking Alpha

Mar 25, 2025
pulisher
Mar 24, 2025

Verve Therapeutics gets FDA approval to begin cholesterol treatment trial - MSN

Mar 24, 2025
pulisher
Mar 24, 2025

Verve Therapeutics Announces Clearance of Investigational - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Verve Therapeutics Says US FDA Clears Verve-102 IND Application for Premature Coronary Artery Disease - MarketScreener

Mar 24, 2025
pulisher
Mar 24, 2025

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-102, an Investigational Gene Editing Medicine Designed to Durably Lower Cholesterol After a Single Dose - The Manila Times

Mar 24, 2025
pulisher
Mar 24, 2025

Game-Changing FDA Green Light: Verve's One-Time Gene Therapy Takes On High Cholesterol - Stock Titan

Mar 24, 2025
pulisher
Mar 22, 2025

Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire

Mar 22, 2025
pulisher
Mar 21, 2025

VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Mar 21, 2025
pulisher
Mar 17, 2025

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Bought by Arizona State Retirement System - Defense World

Mar 17, 2025
pulisher
Mar 16, 2025

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Bought by US Bancorp DE - Defense World

Mar 16, 2025
pulisher
Mar 14, 2025

Verve Therapeutics Inc (VERV): Significant Improvements, Worth Considering - Stocks Register

Mar 14, 2025
pulisher
Mar 08, 2025

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by Rhumbline Advisers - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

IFP Advisors Inc Boosts Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

(VERV) Technical Data - Stock Traders Daily

Mar 06, 2025
pulisher
Mar 05, 2025

Verve Therapeutics (NASDAQ:VERV) Shares Gap Down After Analyst Downgrade - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

Verve Therapeutics (NASDAQ:VERV) Price Target Cut to $15.00 by Analysts at Royal Bank of Canada - Defense World

Mar 05, 2025
pulisher
Mar 04, 2025

Verve Therapeutics price target lowered to $15 from $17 at RBC Capital - TipRanks

Mar 04, 2025
pulisher
Mar 04, 2025

RBC Cuts Price Target on Verve Therapeutics to $15 From $17, Keeps Outperform, Speculative Risk - Marketscreener.com

Mar 04, 2025
pulisher
Mar 03, 2025

How Verve Therapeutics Is Attracting Talent: New Equity Compensation Package Details - StockTitan

Mar 03, 2025
pulisher
Mar 03, 2025

Verve Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - ACCESS Newswire

Mar 03, 2025
pulisher
Mar 03, 2025

Analysts Set Expectations for VERV Q1 Earnings - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

Verve Therapeutics, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your RightsVERV - ACCESS Newswire

Mar 02, 2025
pulisher
Mar 02, 2025

HC Wainwright Forecasts Strong Price Appreciation for Verve Therapeutics (NASDAQ:VERV) Stock - Defense World

Mar 02, 2025
pulisher
Mar 01, 2025

Investors who lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - ACCESS Newswire

Mar 01, 2025
pulisher
Mar 01, 2025

Verve Therapeutics (VERV) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 01, 2025
pulisher
Feb 28, 2025

H.C. Wainwright lifts VERVE Therapeutics price target to $15 By Investing.com - Investing.com Canada

Feb 28, 2025
pulisher
Feb 28, 2025

Promising Progress and Strategic Partnerships Position Verve Therapeutics as a Compelling Buy Opportunity - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Verve Can Shrug Off Vertex Loss But Lilly Opt-In Is Crucial - News & Insights

Feb 28, 2025
pulisher
Feb 28, 2025

Verve TherapeuticsKey Data Catalysts, Major Share Price Volatility In Play In Q2 - Seeking Alpha

Feb 28, 2025
pulisher
Feb 28, 2025

Buy Rating for Verve Therapeutics: Promising Program Progress and Strong Financial Position - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

Verve Therapeutics: Buy Rating Backed by Promising VERVE-102 Program and Strategic Catalysts - TipRanks

Feb 28, 2025
pulisher
Feb 28, 2025

VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire

Feb 28, 2025
pulisher
Feb 28, 2025

Verve Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance UK

Feb 28, 2025
pulisher
Feb 27, 2025

Verve Therapeutics Reports 2024 Financial Results and Pipeline Progress - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Verve Therapeutics: Q4 Earnings Snapshot - Houston Chronicle

Feb 27, 2025
pulisher
Feb 27, 2025

Verve Therapeutics earnings beat by $0.10, revenue topped estimates - Investing.com Canada

Feb 27, 2025
pulisher
Feb 27, 2025

Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 27, 2025

Verve Therapeutics reports Q4 EPS (58c), consensus (67c) - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Vertex ends gene editing research pact with Verve - BioPharma Dive

Feb 27, 2025
$60.58
price down icon 3.01%
$69.18
price down icon 5.66%
$17.36
price down icon 8.20%
$31.11
price down icon 2.14%
$88.05
price down icon 4.30%
biotechnology ONC
$238.51
price down icon 9.76%
Kapitalisierung:     |  Volumen (24h):